Recently, Kexing Biopharm's innovative drug "GB19 Injection" for the treatment of systemic lupus erythematosus (SLE) received approval from National Medical Products Administration (NMPA) to conduct clinical trials in China.
Differentiated Innovative Targeting Mechanism
GB19 Injection targets BDCA2, a receptor specifically expressed on the surface of plasmacytoid dendritic cells (pDCs). Its mechanism of action is distinct from that of currently approved therapies that primarily targeting the B-cell pathway. By specifically binding to BDCA2, GB19 inhibits the production of type I interferon by pDC cells, thereby modulating the pathogenic feedback loop between innate and adaptive immunity. In preclinical studies, GB19 demonstrated high potency, favorable bioavailability, sustained target inhibition for over 90 days, low immunogenicity, and an excellent safety profile. If successfully developed, it is expected to provide new treatment options for patients with autoimmune diseases associated with interferon pathway dysregulation including SLE.
SLE Enters a New Stage of Treatment
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease related to multiple factors, including genetic susceptibility, sex hormones, and environmental trigger such as infection. Its main clinical characteristics include multi-system and multi-organ involvement, recurrent relapses, and the immune –mediated damage to self-tissues. SLE can lead to various complications, including lupus nephritis and neuropsychiatric manifestations, posing serious threats to patients' survival and quality of life. The global patient population is large, with a higher incidence in women of childbearing age compared with in men.
With increased global awareness of SLE and advancements in the development of novel biologics, future SLE treatment will become more precise and personalized. Treatment goals will evolve from simply controlling disease activity to achieving comprehensive remission with low activity, clinical remission, and minimal long-term damage.
The approval of GB19 for clinical trials is a significant achievement for the company's continuous innovation in the treatment of autoimmune diseases and an important step in its global strategy for innovative drugs. Kexing Biopharm adheres to an "innovation + internationalization" strategy, deeply exploring unmet clinical needs in oncology and autoimmune diseases, and is committed to becoming an innovative international biopharmaceutical company.
https://www.kexingbiopharm.com/
Kexing Biopharm